Hier finden Sie den Zugang zur Notfallseite, Kontaktinformationen, Barrierefreiheits-Einstellungen, die Sprachwahl und die Suchfunktion.

Navigation öffnen

AG Prof. Dr. med. Frederik Damm

The research group of Frederik Damm investigates genetic aberrations of hematologic malignancies. 

Sie befinden sich hier:

Focus of research

The research group of Frederik Damm focuses on genetic events defining early steps during leukemo-/ lymphomagenesis using several molecular biology techniques. Combinations of various sequencing technologies using bulk and single-cell approaches help to develop novel models of precision oncology.  A broad national and international collaborating network supports investigations of rare tumor entities and/or molecularly defined subgroups.

Prof. Dr. med. Frederik Damm

Geschäftsführender Oberarzt, Direktor Molekulares Krebsforschungszentrum (MKFZ)

CVK: Campus Virchow-Klinikum

News and announcements

  • Our work on PMBCL genetics got selected for oral presentation within the Presidential Symposium at EHA 2022 in Vienna
  • ​​​​​​AG Damm receives "José Carreras Best Paper Award 2020"
  • Prof. Damm receives "Hector Forschungspreis 2020"
  • Dr. Frick receives Curt-Meyer Gedächtnispreis 2019
  • PD Dr. Damm receives DGHO Acute Leukemia Research Award 2019

Selected publications

  • Briest F, Noerenberg D, Hennch C, ..., Damm F. Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma. Leukemia (accepted).  
  • Arends CM, Liman TG, Strzelecka PM, ..., Damm F. Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke. Blood (2022). doi: 10.1182/blood.2022017661 PubMed
  • Arends CM, Dimitriou S, Stahler A, ..., Damm F. Clonal hematopoiesis associates with improved survival in metastatic colorectal cancer patients from the FIRE-3 trial. Blood (2022). doi: 10.1182/blood.2021014108 PubMed
  • Christen F, Hablesreiter R, Hoyer K, ..., Damm F. Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9. Leukemia (2022). doi: 10.1038/s41375-021-01469-x PubMed
  • Hoyer K, Hablesreiter R, Inoue Y, ..., Damm F. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. EBioMedicine (2021). doi: 10.1016/j.ebiom.2021.103327 PubMed
  • Mylonas E, Yoshida K, Frick M, ..., Damm F. Single-cell analysis based dissection of clonality in myelofibrosis. Nature Communications (2020). doi: 10.1038/s41467-019-13892-x PubMed
  • Christen F, Hoyer K, Yoshida K, ..., Damm F. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood (2019). doi: 10.1182/blood-2018-05-852822 PubMed
  • Frick M, Chan W, Arends CM, ..., Damm F. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology (2019). doi: 10.1200/JCO.2018.79.2184 PubMed
  • Arends CM, Galan-Sousa J, Hoyer K, …, Damm F. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia (2018). doi:10.1038/s41375-018-0047-7 PubMed
  • Young E, Noerenberg D, Mansouri L, ..., Damm F. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia 31, 1547–1554 (2017). doi:10.1038/leu.2016.359 PubMed
  • Mansouri L, Noerenberg D, Young E, ..., Damm F. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood 128, 2666–2670 (2016). doi:10.1182/blood-2016-03-704528 PubMed
  • Damm F, Mylonas E, Cosson A, et al. Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. Cancer Discovery 4, 1088–1101 (2014). doi:10.1158/2159-8290.CD-14-0104 PubMed
  • Damm F, Chesnais V, Nagata Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 122, 3169–3177 (2013). doi:10.1182/blood-2012-11-469619 PubMed
  • Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 119, 3211–3218 (2012). doi:10.1182/blood-2011-12-400994 PubMed